These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303 [TBL] [Abstract][Full Text] [Related]
44. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Vega MI; Baritaki S; Huerta-Yepez S; Martinez-Paniagua MA; Bonavida B Leuk Lymphoma; 2011 Jan; 52(1):108-21. PubMed ID: 21133714 [TBL] [Abstract][Full Text] [Related]
45. 4. Antibody therapy for malignant lymphoma. Tobinai K Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608 [TBL] [Abstract][Full Text] [Related]
46. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278 [TBL] [Abstract][Full Text] [Related]
47. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. Bonavida B; Vega MI Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340 [TBL] [Abstract][Full Text] [Related]
48. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337 [TBL] [Abstract][Full Text] [Related]
49. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581 [TBL] [Abstract][Full Text] [Related]
50. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Dillman RO Semin Oncol; 2003 Aug; 30(4):434-47. PubMed ID: 12939712 [TBL] [Abstract][Full Text] [Related]
51. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Smith MR Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843 [TBL] [Abstract][Full Text] [Related]
53. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248 [TBL] [Abstract][Full Text] [Related]
54. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Zhou X; Hu W; Qin X Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537 [TBL] [Abstract][Full Text] [Related]
55. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study. Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C MAbs; 2012; 4(4):488-96. PubMed ID: 22647435 [TBL] [Abstract][Full Text] [Related]
56. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126 [TBL] [Abstract][Full Text] [Related]
57. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. Musto P; D'Auria F Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115 [TBL] [Abstract][Full Text] [Related]
59. CD20-targeted therapy: the next generation of antibodies. van Meerten T; Hagenbeek A Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667 [TBL] [Abstract][Full Text] [Related]
60. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]